We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Probe Detects HIV Protease and Toxicity of Drugs

By LabMedica International staff writers
Posted on 11 Oct 2010
A molecular probe has been developed that can simultaneously detect the presence of Human immunodeficiency viral (HIV) protease and the toxic levels of chemotherapy. More...


A screening system has been created that by applying fluorescent proteins, one green and one red, they generate Förster resonance energy transfer signals responsive to HIV-1 protease inhibition and activity. The probe can be used to investigate the efficacy and efficiency of HIV drugs, some of which are so toxic that many patients elect to stop treatment.

Förster resonance energy transfer is a mechanism of energy transfer between a donor and receptor chromophore, which is the part of a molecule that is responsible for its color. The energy transfer prompts reactions from cells in the form of color. In the absence of protease inhibitors from various compounds, the investigators observed green and yellow cells. When protease inhibitors were added to cells, they showed a red color.

Currently, treatment of HIV infection depends heavily upon a strategy referred to as highly active antiretroviral therapy, or HAART, in which drugs that inhibit HIV-1 protease are combined with drugs that suppress virus replication. Proteases are a family of enzymes that break down polyproteins and are essential for the life cycle of HIV. Although HAART has reduced mortality, it has significant side effects. A quarter of patients with HIV stop therapy within the first year due to symptoms related to its high toxicity.

Sha Jin, Ph.D., an assistant professor at the University of Arkansas (Fayetteville, AR, USA), who developed the probe, said, "We confirmed that compounds nelfinavir and lopinavir were toxic to cells, since many healthy cells died after two days incubation; indinavir, sequinavir, and ritonavir showed less toxicity." Because the drugs are expensive, patients in low-income countries start treatment at the acquired immunodeficiency syndrome (AIDS) stage of the disease, which leads to higher morbidity and mortality rates. Most importantly, existing treatment for HIV cannot eradicate the virus from patients.

Related Links:

University of Arkansas




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.